CLINUVEL PHARMACEUTICALS LIMITED — Director's Dealing 2021

May 31, 2021

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01. Amended 01/01/11.

Name of entity CLINUVEL PHARMACEUTICALS LTD ABN 88 089 644 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Philippe Wolgen
Date of last notice	05 March 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust.

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct or indirect interest	Direct Interest (Ordinary Shares)	Direct Interest (Ordinary Shares)	Direct Interest (Ordinary Shares)
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.
Date of change		26 May 2021 to 31 May 2021
No. of securi	ties held prior to change	3,400,696 Ordinary Shares (includes 2,199,810 Ordin		arynalceus
		SharesPerforRights	beneficially held in the Clinuvel Conditiomance Rights Scheme Trust and the PerformanPlan Trust)
		1,513,milest	750UnlistedPerformanceRights(varioones, expirydate 20/11/2023)
Class		Ordina	ry Shares
Number acqu	ired	Nil
Number disp	osed	102,70	0

Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$3,127,366.02
No. of securities held after change	3,297,996 Ordinary Shares (includes 2,199,810 OrdinaryShares beneficially held in the Clinuvel ConditionalPerformance Rights Scheme Trust and the PerformanceRights Plan Trust)1,513,750UnlistedPerformanceRights(variousmilestones, expiry date 20/11/2023)
Nature of changeExample: on-market trade, off-market trade, exercise of options, issueof securities under dividend reinvestment plan, participation in buy-back	On-market sale, representing 3.02% of his holdings. Thedisposal of shares is to meet personal commitments andannual rebalancing of portfolio.Dr Wolgen does not receive annual fixed equity awards oroptions as part of his remuneration but is eligible toexercise Performance Rights conditional on meetingcertain specified corporate Performance Conditionsattached to the Performance Rights.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation

Page 2

Appendix 3Y Change of Director’s Interest Notice

Interest after change

Part 3 –[+] Closed period

art 3 –+Closed period	art 3 –+Closed period	art 3 –+Closed period
Were the interests in the securities or contracts detailed abovetraded during a+closed period where prior written clearancewas required?			No
If so, wasproceed d	rior written clearance rovided to allow the trade to		n/a
	puring this period?
If prior wriprovided?	tt l idd ht	t thi
	en cearance was prove, on wa	ae was s	n/a

Page 3